Loading…
Loading…
Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the Fidelity MSCI Health Care Index ETF (FHLC) is a passively managed exchange traded fund launched on October 21, 2013.
Fidelity MSCI Health Care Index ETF (FHLC) provides broad sector exposure with significantly lower fees than VanEck Biotech ETF (BBH). BBH focuses on just 25 holdings in the biotech space while FHLC holds more than 300 positions across the entire healthcare industry.
Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and higher dosing—effectively extends product lifecycles and drives shareholder value.
iShares Global Healthcare ETF provides exposure to international markets, while Fidelity MSCI Health Care Index ETF focuses exclusively on U.S.-based companies. Fidelity MSCI Health Care Index ETF maintains a significantly lower expense ratio than iShares Global Healthcare ETF.
Fidelity MSCI Health Care Index ETF (FHLC) offers a lower expense ratio and higher dividend than the iShares U.S. Healthcare ETF (IYH). IYH maintains a more concentrated portfolio, with 101 holdings compared to FHLC's 338 positions.
Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story.
The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by the President of the United States and quietly outperforming nearly every healthcare benchmark anyway.
The Fidelity MSCI Health Care Index ETF (NYSEARCA:FHLC) is down about 5% year to date while the S&P 500 is up 7%.